Current GLP1 treatments are peptidebased injectables typically administered once weekly
In the SURMOUNT5 trial, participants lost an average of 20.2 % of their baseline body weight over 72 weeks with tirzepatide, with a greater proportion achieving weight-loss thresholds of 1525 % compared with semaglutide
Platinum: Because this test is so comprehensive, it requires a larger volume of blood (a venous sample) and must be performed by a professional at a clinic or via a nurse home visit
GLP-1 medications are highly sensitive to heat and freezing, requiring a temperature-controlled environment that balances stability, compliance, and patient care
Accordingly, approved indications expanded in early 2024 to include not only reduction of hyperglycemia, but also weight management in non-diabetic patients, and even cardiovascular risk reduction in patients with elevated weight and comorbid cardiovascular disease
Step 2: Hormone Foundation First For most menopausal women, we start with BHRT establishing the hormonal foundation before adding peptides